Sophia Karagiannis, Ph.D.

Professor of Translational Cancer Immunology at King's College London School of Medicine

Speaker

Professor Sophia Karagiannis is a translational cancer immunologist with academic and biotechnology experience in the USA and UK. She heads a cancer antibody discovery team at King’s College London focused on dissecting cancer patient-derived B cells and their expressed antibodies, and on the design of Fc-engineered antibodies of different isotypes and of antibody-drug conjugates for the treatment of solid tumours. Her group is the first to design, evaluate and translate anti-tumour IgE class antibodies from concept to clinical testing. Sophia is founder of Epsilogen Ltd, the first immuno-oncology company dedicated to developing IgE-based anti-cancer agents.